Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

Summary

Patients with severe mental illness (SMI) die younger than persons in the general population. Much of the excess mortality for SMI patients is attributable to cardiovascular disease, and is exacerbated by treatment with second-generation antipsychotics (2GAs). Although the cardiovascular risks are well-known, and safe, efficacious therapy exists, few SMI patients receive cardiovascular prevention drugs. Care delivery fragmentation and poor patient adherence are central problems to reducing cardiovascular risks for patients with SMI. To address these problems, we propose to conduct a multi-site, open-label, randomized controlled trial comparing an initial treatment strategy of free, fixed-doses of two generic, cardiovascular prevention drugs (statins and angiotensin drugs) delivered within mental health clinics versus usual treatment. The study will include adult patients (18+ years old) with schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or psychosis not otherwise specified (NOS) who have received 2GAs treatment within the past six months from within four mental health clinics in the Boston area. We have three aims: 1) to compare the proportions of subjects in each arm who are receiving cardiovascular drug treatment and are adherent to therapy during 12-months of follow-up; 2) to compare changes in composite (e.g., Framingham scores) and individual (e.g., lipid levels) cardiovascular risk factor levels using an intent-to-treat (ITT) approach; and 3) to compare risk factor levels, accounting for variation in adherence over time, using causal inference techniques to estimate the per-protocol effect of the intervention. Our three aims examine whether this low cost, streamlined treatment strategy increases the numbers of subjects receiving cardiovascular prevention therapy and improves cardiovascular risk levels. We will follow subjects for 12 months, and collect interview and biometric data at baseline and over the following 12 months. Subjects will have the option to continue for another 12 months, during which we will continue to collect interview and biometric data, but will not prescribe cardiovascular medications. This population-based initial treatment strategy could be an effective and efficient approach for overcoming traditional barriers to cardiovascular disease prevention within the SMI population. Findings from this study will inform efforts to improve care and outcomes, and to enhance survival for patients with severe mental illness.

Conditions

• Serious Mental Illness
• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder
• Cardiovascular Disease
• Major Depressive Disorder
• Psychosis NOS

Interventions

DRUG

Simvastatin

3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors

DRUG

Losartan

Angiotensin II receptor antagonist

Sponsors & Collaborators

• Michael J. Gill Mental Health Clinic

  collaborator OTHER

• Massachusetts Mental Health Center

  collaborator OTHER

• Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital

  collaborator UNKNOWN

• The Edinburg Center

  collaborator OTHER

• Mclean Hospital

  lead OTHER

Principal Investigators

• Dost Ongur, MD PhD · Mclean Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

89 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-02-28

Primary Completion

2020-10-31

Completion

2021-10-31

FDA Drug

Yes

Countries

• United States

Study Locations